Product Information
VERAPAMIL ER PM 300 MG CAPSULE is a generic product labeled by Lannett Company Inc., priced at $7.9598 per EA under NDC 62175048737. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Nov 25, 1998.
Strength
300 mg/1
Manufacturer
Lannett Company Inc.NDC
62175048737
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
VERAPAMIL HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA020943FDA Approved
11/25/1998
On Market Since
11/25/1998
Pharmacological Classes
Price Statistics
The NADAC for VERAPAMIL ER PM 300 MG CAPSULE has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 324.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.9598 per EA |
|---|---|
| All-time high | $8.9342 (Jan 12, 2022) |
| All-time low | $1.4464 (Oct 17, 2018) |
| 52-week high | $8.0429 |
| 52-week low | $7.5962 |
| Median price | $6.7359 |
| Average price | $5.2071 |
| Largest weekly change | +271.3% (Apr 17, 2019) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
-0.8%
6M
+0.6%
1Y
+4.8%
3Y
-8.3%
5Y
+3.1%
All
+324.2%
Last surveyed Aug 19, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lannett Company Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Verapamil Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VERAPAMIL ER PM 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for VERAPAMIL ER PM 300 MG CAPSULE, manufactured by Lannett Company Inc., is $7.9598 per EA (NDC 62175048737), effective Aug 19, 2026.
How has the price of VERAPAMIL ER PM 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for VERAPAMIL ER PM 300 MG CAPSULE has risen 324.2%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VERAPAMIL ER PM 300 MG CAPSULE?
Since Nov 28, 2013, the NADAC for VERAPAMIL ER PM 300 MG CAPSULE has ranged from a low of $1.4464 (Oct 17, 2018) to a high of $8.9342 (Jan 12, 2022), with a median of $6.7359 per EA.
Are there cheaper alternatives to VERAPAMIL ER PM 300 MG CAPSULE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VERAPAMIL ER PM 300 MG CAPSULE, is $7.9202 per EA — about 0% below VERAPAMIL ER PM 300 MG CAPSULE.
Who manufactures VERAPAMIL ER PM 300 MG CAPSULE?
VERAPAMIL ER PM 300 MG CAPSULE (NDC 62175048737) is labeled by Lannett Company Inc., and CMS classifies it as a generic product.